INTI · Inhibitor Therapeutics, Inc. · Executive Compensation
$0.11
At close · Oct 16
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions and events raise substantial doubt about the Company's ability to continue as a going concern. ... Because management's plans have not yet been fully executed and are not within the Company's control, the implementation of such plans cannot be considered probable. As a result, the Company has concluded that management's plans do not currently alleviate substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$19.12M
Shares
173.79M
Volume · Oct 16
3900
Avg daily vol (3M)
15.6K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Francis E. O'Donnell | Executive Chairman and Chief Executive Officer | $1,118,630 |
| Francis E. O'Donnell, Jr. | Executive Chairman and Chief Executive Officer | $1,118,630 |
| James A. McNulty | Interim Chief Financial Officer, Secretary and Treasurer | $362,574 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Francis E. O'Donnell | Executive Chairman and Chief Executive Officer | $1,137,886 |
| Francis E. O'Donnell, Jr. | Executive Chairman and Chief Executive Officer | $1,137,886 |
| James A. McNulty | Interim Chief Financial Officer, Secretary and Treasurer | $359,756 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Ronald E. Osman | Director | Appointed | 2026-09-18 |
| Michelle Yanez | Director | Appointed | 2026-09-18 |
| Michael Jerman | Director | Appointed | 2026-09-18 |
| Niraj Vasisht | Director | Appointed | 2026-09-18 |
| Samuel J. Sears | Director | Appointed | 2026-09-18 |
| Francis E. O'Donnell | Director | Appointed | 2026-09-18 |
| Michelle Yanez | independent director | Appointed | 2023-10-18 |
| Ronald E. Osman | Director (non-independent director) | Appointed | 2023-08-29 |
| Michael Jerman, CPA. | independent member of its Board | Appointed | 2023-05-31 |
| Michelle Yanez | Board of Directors | Resigned | 2023-05-31 |
| James A. McNulty | Chief Financial Officer and Treasurer (CFO) | Appointed | 2022-12-19 |
| Michelle Yanez, MBA | independent member of its Board | Appointed | 2022-12-19 |
| Niraj Vasisht, Ph.D. | independent member of its Board | Appointed | 2022-12-19 |
| Samuel J. Sears, Jr. | independent member of its Board | Appointed | 2022-12-19 |
| James A. McNulty, CPA | Chief Financial Officer, Treasurer and Secretary of the Company | Appointed | 2022-12-19 |
| Francis E. O'Donnell, Jr., M.D. | Chief Executive Officer of the Company | Appointed | 2022-12-19 |
| Francis E. O'Donnell, Jr., M.D. | Executive Chairman of its Board | Appointed | 2022-12-19 |
| Garrison J. Hasara | officer positions | Resigned | 2022-12-19 |
| Nicholas J. Virca | officer positions | Resigned | 2022-12-19 |
| Robert D. Martin | Director | Resigned | 2022-12-19 |
| R. Dana Ono | Director | Resigned | 2022-12-19 |
| Stefan J. Cross | Director | Resigned | 2022-12-19 |
| W. Mark Watson | Director | Resigned | 2022-12-19 |
Leadership
- Francis E. O'Donnell CEO, Board Member
- Francis E. O'Donnell, Jr. CEO, Chairman
- Francis E. O'Donnell, Jr., M.D. CEO, Chairman
- James A. McNulty CFO
- James A. McNulty, CPA CFO
- Michael Jerman Board Member
- Michael Jerman, CPA. Board Member
- Michelle Yanez Board Member
- Michelle Yanez, MBA Board Member
- Niraj Vasisht Board Member
- Niraj Vasisht, Ph.D. Board Member
- Ronald E. Osman Board Member
- Samuel J. Sears Board Member
- Samuel J. Sears, Jr. Board Member